Low-density lipoprotein cholesterol in patients with stable coronary heart disease - Is it time to shift our goals?

New England Journal of Medicine

Volumn 352, Issue 14, 2005, Pages 1483-1484

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS; BLOOD; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DOSE RESPONSE; NOTE; RISK;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; RISK;

EID: 15944394012     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058052     Document Type: Editorial

References (7)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. [Erratum, Circulation 2004;110:763.]
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. [Erratum, Circulation 2004;110:763.]
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
5. Lipka LJ. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev 2003;21:293-312.
6. Walldius G, Jungner I, Holme I, Aastveit HI, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
7. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.